Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism

por Wang, Jinhai, Fang, Ying, Fan, R. Andrea, Kirk, Christopher J.
Publicado 2021

Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors

por Kirk, Christopher J., Muchamuel, Tony, Wang, Jinhai, Fan, R. Andrea
Publicado 2021

Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis

por Basler, Michael, Mundt, Sarah, Muchamuel, Tony, Moll, Carlo, Jiang, Jing, Groettrup, Marcus, Kirk, Christopher J
Publicado 2014

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

por Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P. Leif, Bennett, Mark K., Kirk, Christopher J.
Publicado 2011

Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses

por Muchamuel, Tony, Fan, R. Andrea, Anderl, Janet L., Bomba, Darrin J., Johnson, Henry W. B., Lowe, Eric, Tuch, Brian B., McMinn, Dustin L., Millare, Beatriz, Kirk, Christopher J.
Publicado 2023

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

por Niewerth, Denise, Kaspers, Gertjan JL, Assaraf, Yehuda G, van Meerloo, Johan, Kirk, Christopher J, Anderl, Janet, Blank, Jonathan L, van de Ven, Peter M, Zweegman, Sonja, Jansen, Gerrit, Cloos, Jacqueline
Publicado 2014

Inhibition of the Sec61 translocon overcomes cytokine‐induced glucocorticoid resistance in T‐cell acute lymphoblastic leukaemia

por Meyer, Lauren K., Delgado‐Martin, Cristina, Sharp, Phillip P., Huang, Benjamin J., McMinn, Dustin, Vincent, Tiffaney L., Ryan, Theresa, Horton, Terzah M., Wood, Brent L., Teachey, David T., Taunton, Jack, Kirk, Christopher J., Hermiston, Michelle L.
Publicado 2022

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

por Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Publicado 2016

Signal peptide mimicry primes Sec61 for client-selective inhibition

por Rehan, Shahid, Tranter, Dale, Sharp, Phillip P., Craven, Gregory B., Lowe, Eric, Anderl, Janet L., Muchamuel, Tony, Abrishami, Vahid, Kuivanen, Suvi, Wenzell, Nicole A., Jennings, Andy, Kalyanaraman, Chakrapani, Strandin, Tomas, Javanainen, Matti, Vapalahti, Olli, Jacobson, Matthew P., McMinn, Dustin, Kirk, Christopher J., Huiskonen, Juha T., Taunton, Jack, Paavilainen, Ville O.
Publicado 2023

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

por Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G, Niewerth, Denise, van Meerloo, Johan, Cloos, Jacqueline, van der Veer, Michael, Scheffer, George L, Peters, Godefridus J, Chan, Elena T, Anderl, Janet L, Kirk, Christopher J, Zweegman, Sonja, Dijkmans, Ben AC, Lems, Willem F, Scheper, Rik J, de Gruijl, Tanja D, Jansen, Gerrit
Publicado 2013